KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Research & Development (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Research & Development data on record, last reported at $34.8 million in Q4 2025.

  • For Q4 2025, Research & Development fell 35.84% year-over-year to $34.8 million; the TTM value through Dec 2025 reached $186.2 million, down 2.38%, while the annual FY2025 figure was $186.2 million, 2.38% down from the prior year.
  • Research & Development reached $34.8 million in Q4 2025 per AMRX's latest filing, down from $63.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $63.4 million in Q3 2025 and bottomed at $34.8 million in Q4 2025.
  • Average Research & Development over 5 years is $46.9 million, with a median of $48.1 million recorded in 2021.
  • Peak YoY movement for Research & Development: soared 47.67% in 2024, then tumbled 35.84% in 2025.
  • A 5-year view of Research & Development shows it stood at $51.9 million in 2021, then fell by 19.21% to $41.9 million in 2022, then increased by 9.97% to $46.1 million in 2023, then increased by 17.75% to $54.3 million in 2024, then tumbled by 35.84% to $34.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $34.8 million in Q4 2025, $63.4 million in Q3 2025, and $48.0 million in Q2 2025.